Merck's ifinatamab deruxtecan wins FDA Breakthrough Therapy status for treating adults with extensive-stage small cell lung ...

Wrapping up Q2 earnings, we look at the numbers and key takeaways for the branded pharmaceuticals stocks, including Merck ...

After six days of gains, shares dropped, reflecting mixed momentum. See insights on earnings, cost-cutting, and analyst ...

GMO’s 13F portfolio grew to $33.23B in Q2 2025, with Microsoft, Meta, Alphabet, Oracle, and Apple as top holdings. Read more ...

Merck & Co., Inc. (NYSE:MRK) is included in our list of the 10 Most Undervalued Value Stocks to Buy Now. On August 12, 2025, ...

Additionally, a study published in July 2025 examined the use of methotrexate as first-line treatment for pulmonary ...

CHENNAI: Agriculture Minister MRK Panneerselvam dismissed the charges levelled by PMK leader Anbumani Ramadoss that Chief ...

Merck & Co., Inc. (NYSE: MRK) is one of the best depressed stocks to buy in 2025. On August 2, the company completed the ...

Skyhawk's RNA tech could be Merck's next blockbuster play as drug setbacks and looming patent cliffs force a reinvention.

Japan 1st Quarter Ended June 30 GROUP 2025 2024 Revenue Y4.72 bln Y4.46 bln Operating Profit (Y458.00 mln) (Y379.00 mln) Pretax Profit (Y313.00 mln) (Y332.00 mln) Net Profit (Y182.00 mln) (Y266.00 mln ...

Shares of Gilead Sciences, Inc. (GILD) gained 7.3% after the company reported solid results for the second quarter of 2025 ...

Merck & Co (NYSE: MRK) and Daiichi Sankyo (TYO: 4568) have received Breakthrough Therapy designation from the US regulator ...